Prosecution Insights
Last updated: August 06, 2026
Application No. 18/614,982

Serotonin Receptor Agonists and Methods of Making and Using the Same

Non-Final OA §102
Filed
Mar 25, 2024
Priority
Oct 04, 2021 — provisional 63/251,989 +1 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kuleon LLC
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
4m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
875 granted / 1232 resolved
+11.0% vs TC avg
Minimal +0% lift
Without
With
+0.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
103 currently pending
Career history
1296
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.8%
-6.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1232 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions 2. Applicant’s election without traverse of Group I, and species of compound PNG media_image1.png 126 154 media_image1.png Greyscale , in the reply filed on May 29, 2026 is acknowledged. 3. Examination followed guidelines provided by MPEP 803.02. The elected species appeared to be novel and non-obvious over the prior art. Therefore, the search and examination was extended. Prior art was found that anticipates the claims with respect to nonelected species. The Markush claims were rejected and claims to nonelected species were withdrawn from further consideration. The claims were searched to the extent of the elected species and additionally to the nonelected species shown below. 4. Claims 39, 45-47, 49-52 and 54 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected subject matter. Election was made without traverse in the reply filed on May 29, 2026. Information Disclosure Statement 5. The information disclosure statements (dated March 25, 2024 and May 29, 2026) were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The statements were considered. Signed copies of form 1449 are enclosed herewith. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 6. Claim(s) 34, 36-37, 40-42 and 48 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2104411-00-7 ( PNG media_image2.png 278 372 media_image2.png Greyscale ). The reference has a date of 2017 which antedates the present claims having a filing date of October 3, 2022 and priority claim to provisional application dated October 4, 2021. The compound corresponds to the present claims in the following manner: A=heterocycle substituted with methyl; Z6=C(R6=H); Z7=C(R7=H); W1=N(R1=H); R2=R3=R3’=H; W2=(CH2)2; X=H; Y=Me. 7. Claim(s) 34-36, 38, 40, 41 and 53 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 82173-82-8 ( PNG media_image3.png 230 344 media_image3.png Greyscale ). The reference has a date of 1984 which antedates the present claims having a filing date of October 3, 2022 and priority claim to provisional application dated October 4, 2021. The compound corresponds to the present claims in the following manner: A=heterocycle; Z6=C(R6=H); Z7=C(R7=H); W1=N(R1=H); R2=R3=R3’=H; W2=CH2; X=Y=C3 alkyl. 8. Claim(s) 34, 36, 37, 40-44, 48 and 53 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 135360-97-3 ( PNG media_image4.png 236 310 media_image4.png Greyscale ). The reference has a date of 1991 which antedates the present claims having a filing date of October 3, 2022 and priority claim to provisional application dated October 4, 2021. The compound corresponds to the present claims in the following manner: A=heterocycle; Z6=C(R6=H); Z7=C(R7=H); W1=N(R1=H); R2=R3=R3’=H; W2=CH2; X=Y=methyl. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Mar 25, 2024
Application Filed
Jul 14, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Patent 12674026
PROCESS FOR PREPARING POLYOL-BASED ESTERS OF ACYL-CAPPED HYDROXY CARBOXYLIC ACIDS
4y 6m to grant Granted Jul 07, 2026
Patent 12661353
SPT5 INHIBITORS AND USES THEREOF
4y 10m to grant Granted Jun 23, 2026
Patent 12662459
METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES
2y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.1%)
2y 8m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1232 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month